한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제41권3호
  • /
  • Pages.170-177
  • /
  • 2024
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

A Rare Case of Canine Pericardial Malignant Mesothelioma: Clinicopathologic Findings, Diagnostic Investigations, and Clinical Course with Epirubicin Treatment

  • Jun-Hyuk Min (College of Veterinary Medicine, Jeju National University) ;
  • Jiwoong Yoon (College of Veterinary Medicine, Jeju National University) ;
  • Sooyoung Son (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Jeju National University) ;
  • Woo-Jin Song (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Jeju National University) ;
  • Siheon Lee (24hr WISE Animal Medical Center) ;
  • Youngmin Yun (Research Institute of Veterinary Medicine, College of Veterinary Medicine, Jeju National University) ;
  • Hyunjung Park (College of Veterinary Medicine, Jeju National University) ;
  • Jongtae Cheong (College of Veterinary Medicine, Jeju National University) ;
  • Alba Maria M. Shank (IDEXX) ;
  • Myung-Chul Kim (Research Institute of Veterinary Medicine, College of Veterinary Medicine, Jeju National University)
  • 투고 : 2024.05.29
  • 심사 : 2024.06.12
  • 발행 : 2024.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

An adult male dog was presented for hemorrhagic pericardial effusion. Echocardiography and computed tomography revealed nodule-like lesions on the pericardium. Cytology of pericardial effusion and excisional pericardial lesions indicated neoplastic effusion. Histopathology indicated an inflamed neoplasm with a primary differential diagnosis of hemangiosarcoma and malignant mesothelioma (MM). Immunohistochemistry showed that atypical cells were positive for cytokeratin and vimentin, but negative for CD31, strongly favoring pericardial MM. Postoperative NT-proBNP level remained increased, which led to the administration of epirubicin to minimize potential cardiotoxicity. During the 4 cycles of epirubicin treatment, a total cumulative dose of 108 mg/m2 was administrated and no effusion recurrence was observed. After a month post-completion of chemotherapy, however, pleural effusion was detected with cardiac masses. The owner requested no further diagnostic investigations and chemotherapy. Due to deteriorating conditions, the dog died 132 days after the first presentation. Our case is the first notable attempt to treat canine malignant mesothelioma with epirubicin, providing the clinicopathologic, diagnostic routine, and clinical course of the affected dog.

키워드

과제정보

We express our appreciation to all the pathologists from IDEXX Laboratories involved with the pathology and immunohistochemistry reports used in this study. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) (#RS-2023-00241779). This research was also supported by Regional Innovation Strategy (RIS) through the NRF funded by MOE (#2023RIS-009).

참고문헌

  1. Candido P, Belloni P, Pelliccione M, Corradini GM, Toniolo D, Cozzi C, et al. Weekly epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma. Ann Oncol 2019; 30 Suppl 5: v647-v648. https://doi.org/10.1093/annonc/mdz260.095
  2. Geske JB, Calvin AD. Spontaneous "cardiomegaly" following pericardiectomy. J Card Surg 2009; 24: 695-696. https://doi.org/10.1111/j.1540-8191.2009.00852.x
  3. Inanaga M, Yoneji W, Ozaki K. Localized pleural mesothelioma in a dog. J Comp Pathol 2023; 207: 25-29. https://doi.org/10.1016/j.jcpa.2023.09.006
  4. Jackson J, Richter KP, Launer DP. Thoracoscopic partial pericardiectomy in 13 dogs. J Vet Intern Med 1999; 13: 529-533. https://doi.org/10.1111/j.1939-1676.1999.tb02205.x
  5. Kim SE, Liptak JM, Gall TT, Monteith GJ, Woods JP. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). J Am Vet Med Assoc 2007; 231: 1550-1557. https://doi.org/10.2460/javma.231.10.1550
  6. Lajoinie M, Chavalle T, Floch F, Sayag D, Lanore D, Ponce F, et al. Outcome of dogs treated with chemotherapy for mesothelioma: a retrospective clinical study on 40 cases and a literature review. Vet Comp Oncol 2022; 20: 825-835. https://doi.org/10.1111/vco.12843
  7. Lee YR, Kang MH, Park HM. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin. Can Vet J 2015; 56: 571-574.
  8. Levi M, Parenti F, Muscatello LV, Battaia S, Santilli R, Perego M, et al. Pathological findings of canine idiopathic pericarditis and pericardial mesotheliomas: correlation with clinical and survival data. Vet Sci 2021; 8: 162.
  9. MacDonald KA, Cagney O, Magne ML. Echocardiographic and clinicopathologic characterization of pericardial effusion in dogs: 107 cases (1985-2006). J Am Vet Med Assoc 2009; 235: 1456-1461. https://doi.org/10.2460/javma.235.12.1456
  10. McDonough SP, MacLachlan NJ, Tobias AH. Canine pericardial mesothelioma. Vet Pathol 1992; 29: 256-260. https://doi.org/10.1177/030098589202900312
  11. Moberg HL, Gramer I, Schofield I, Blackwood L, Killick D, Priestnall SL, et al. Clinical presentation, treatment and outcome of canine malignant mesothelioma: a retrospective study of 34 cases. Vet Comp Oncol 2022; 20: 304-312. https://doi.org/10.1111/vco.12777
  12. Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy experience with six dogs. J Vet Intern Med 1991; 5: 227-231. https://doi.org/10.1111/j.1939-1676.1991.tb00953.x
  13. Morey AGN, Wiggen KE, De New K, Karnia JJ. Echocardiographic, thoracic ultrasonographic, and CTA diagnosis of pericardial neoplasia in a dog. Vet Radiol Ultrasound 2023; 64: E1-E5. https://doi.org/10.1111/vru.13168
  14. Mullin CM, Arkans MA, Sammarco CD, Vail DM, Britton BM, Vickery KR, et al. Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs†. Vet Comp Oncol 2016; 14: e171-e183. https://doi.org/10.1111/vco.12131
  15. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14: 1007-1017. https://doi.org/10.1200/JCO.1996.14.3.1007
  16. Sardar MR, Kuntz C, Patel T, Saeed W, Gnall E, Imaizumi S, et al. Primary pericardial mesothelioma unique case and literature review. Tex Heart Inst J 2012; 39: 261-264.
  17. Shang D, Song B, Liu Y. Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma. Cancer Sci 2018; 109: 980-987. https://doi.org/10.1111/cas.13403
  18. Soini Y, Kahlos K, Sormunen R, Saily M, Mantymaa P, Koistinen P, et al. Activation and relocalization of caspase 3 during the apoptotic cascade of human mesothelioma cells. APMIS 2005; 113: 426-435. https://doi.org/10.1111/j.1600-0463.2005.apm_160.x
  19. Stepien RL, Whitley NT, Dubielzig RR. Idiopathic or mesothelioma-related pericardial effusion: clinical findings and survival in 17 dogs studied retrospectively. J Small Anim Pract 2000; 41: 342-347. https://doi.org/10.1111/j.1748-5827.2000.tb03215.x